Monitoring hypoxia and vasculature during bevacizumab treatment in a murine colorectal cancer model

Contrast Media and Molecular Imaging

Volumn 9, Issue 3, 2014, Pages 237-245

  Heijmen, L ^a   ter Voert, E G W ^a   Punt, C J A ^b   Heerschap, A ^a   Oyen, W J G ^a   Bussink, J ^a   Sweep, C G J ^a   Laverman, P ^a   Span, P N ^a   de Geus Oei, L F ^a   Boerman, O C ^a   van Laarhoven, H W M ^a,b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Bevacizumab; Colorectal cancer; Hypoxia; Mechanism of resistance; Tumor vasculature and microenvironment

Indexed keywords

BEVACIZUMAB; CARBONATE DEHYDRATASE IX; GADOMER 17; GLUCOSE TRANSPORTER 1; PIMONIDAZOLE; 1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL; ANGIOGENESIS INHIBITOR; FLUORODEOXYGLUCOSE F 18; MISONIDAZOLE; MONOCLONAL ANTIBODY; NITROIMIDAZOLE DERIVATIVE; RADIOPHARMACEUTICAL AGENT; RADIOSENSITIZING AGENT;

ARTICLE; BLOOD VESSEL PERMEABILITY; COLORECTAL CANCER; DRUG EFFECT; GLUCOSE TRANSPORT; HYPOXIA; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR VASCULARIZATION; TUMOR VOLUME; ANALOGS AND DERIVATIVES; ANIMAL; ANOXIA; BAGG ALBINO MOUSE; BLOOD; COLORECTAL NEOPLASMS; DIAGNOSTIC USE; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; METABOLISM; MOUSE; NEOVASCULARIZATION, PATHOLOGIC; NUDE MOUSE; PATHOLOGY; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANOXIA; ANTIBODIES, MONOCLONAL, HUMANIZED; COLORECTAL NEOPLASMS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUORODEOXYGLUCOSE F18; IMMUNOENZYME TECHNIQUES; MAGNETIC RESONANCE IMAGING; MICE; MICE, INBRED BALB C; MICE, NUDE; MISONIDAZOLE; NEOVASCULARIZATION, PATHOLOGIC; NITROIMIDAZOLES; POSITRON-EMISSION TOMOGRAPHY; RADIATION-SENSITIZING AGENTS; RADIOPHARMACEUTICALS;

EID: 84897386715     PISSN: 15554309     EISSN: 15554317     Source Type: Journal    
DOI: 10.1002/cmmi.1564     Document Type: Article

References (45)

1. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005; 23(5): 1011-1027.
2. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. New Engl J Med 2004; 350(23): 2335-2342.
3. Kabbinavar FF, Schulz J, McCleod M, Patel T, Hamm JT, Hecht JR, Mass R, Perrou B, Nelson B, Novotny WF. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 2005; 23(16): 3697-3705.
4. Saltz LB, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzen F, Cassidy J. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008; 26(12): 2013-2019.
5. Tebbutt NC, Wilson K, Gebski VJ, Cummins MM, Zannino D, van Hazel GA, Robinson B, Broad A, Ganju V, Ackland SP, Forgeson G, Cunningham D, Saunders MP, Stockler MR, Chua Y, Zalcberg JR, Simes RJ, Price TJ. Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. J Clin Oncol 2010; 28(19): 3191-3198.
6. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005; 307(5706): 58-62.
7. Ma J, Waxman DJ. Combination of antiangiogenesis with chemotherapy for more effective cancer treatment. Mol Cancer Ther 2008; 7(12): 3670-3684.
8. Leite de Or, Hamm A, Mazzone M. Growing tumor vessels: more than one way to skin a cat - implications for angiogenesis targeted cancer therapies. Mol Asp Med 2011; 32(2): 71-87.
9. Conley SJ, Gheordunescu E, Kakarala P, Newman B, Korkaya H, Heath AN, Clouthier SG, Wicha MS. Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia. Proc Natl Acad Sci U S A 2012; 109(8): 2784-2789.
10. Yuan X, Qin L, Xiao-Yu L, Qiu-Ya Y, Wei-Wei X, Gao-Lin L. Short-term anti-vascular endothelial growth factor treatment elicits vasculogenic mimicry formation of tumors to accelerate metastasis. J Exp Clin Cancer Res 2012; 31(1): 16.
11. Brown JM, Wilson WR. Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer 2004; 4(6): 437-447.
12. Tredan O, Galmarini CM, Patel K, Tannock IF. Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst 2007; 99(19): 1441-1454.
13. Kindler HL, Niedzwiecki D, Hollis D, Sutherland S, Schrag D, Hurwitz H, Innocenti F, Mulcahy MF, O'Reilly E, Wozniak TF, Picus J, Bhargava P, Mayer RJ, Schilsky RL, Goldberg RM. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol 2010; 28(22): 3617-3622.
14. Ohtsu A, Shah MA, Van Cutsem E, Rha SY, Sawaki A, Park SR, Lim HY, Yamada Y, Wu J, Langer B, Starnawski M, Kang YK. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol 2011; 29(30): 3968-3976.
15. Robert NJ, Dieras V, Glaspy J, Brufsky AM, Bondarenko I, Lipatov ON, Perez EA, Yardley DA, Chan SY, Zhou X, Phan SC, O'Shaughnessy J. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 2011; 29(10): 1252-1260.
16. Proposal to withdraw approval for the breast cancer indication for Avastin (bevacizumab). US Food and Drug Administration, 2012. Available from: http://www.fda.gov/downloads/NewsEvents/Newsroom/UCM280546.pdf.
17. Mees G, Dierckx R, Vangestel C, Van de Wiele C. Molecular imaging of hypoxia with radiolabelled agents. Eur J Nucl Med Mol Imag 2009; 36(10): 1674-1686.
18. Pauwels EK, Ribeiro MJ, Stoot JH, McCready VR, Bourguignon M, Maziere B. FDG accumulation and tumor biology. Nucl Med Biol 1998; 25(4): 317-322.
19. Busk M, Horsman MR, Jakobsen S, Bussink J, van der Kogel A, Overgaard J. Cellular uptake of PET tracers of glucose metabolism and hypoxia and their linkage. Eur J Nucl Med Mol Imag 2008; 35(12): 2294-2303.
20. Contractor KB, Aboagye EO. Monitoring predominantly cytostatic treatment response with 18F-FDG PET. J Nucl Med 2009; 50(suppl 1): 97S-105S.
21. de Langen AJ, van dBV, Lubberink M, Backes WH, Marcus JT, van TH, Pruim J, Brans B, Leffers P, Dingemans AM, Smit EF, Groen HJ, Hoekstra OS. Monitoring response to antiangiogenic therapy in non-small cell lung cancer using imaging markers derived from PET and dynamic contrast-enhanced MRI. J Nucl Med 2011; 52(1): 48-55.
22. Goshen E, Davidson T, Zwas ST, Aderka D. PET/CT in the evaluation of response to treatment of liver metastases from colorectal cancer with bevacizumab and irinotecan. Technol Cancer Res Treat 2006; 5(1): 37-43.
23. Vriens D, de Geus-Oei LF, Heerschap A, van Laarhoven HW, Oyen WJ. Vascular and metabolic response to bevacizumab-containing regimens in two patients with colorectal liver metastases measured by dynamic contrast-enhanced MRI and dynamic 18F-FDG-PET. Clin Colorectal Cancer 2011; 10(1): E1-E5.
24. Hirashima Y, Yamada Y, Tateishi U, Kato K, Miyake M, Horita Y, Akiyoshi K, Takashima A, Okita N, Takahari D, Nakajima T, Hamaguchi T, Shimada Y, Shirao K. Pharmacokinetic parameters from 3-Tesla DCE-MRI as surrogate biomarkers of antitumor effects of bevacizumab plus FOLFIRI in colorectal cancer with liver metastasis. Int J Cancer 2012; 130(10): 2359-2365.
25. Ungersma SE, Pacheco G, Ho C, Yee SF, Ross J, van BN, Peale FV Jr, Ross S, Carano RA. Vessel imaging with viable tumor analysis for quantification of tumor angiogenesis. Magn ResonMed 2010; 63(6): 1637-1647.
26. 2*-based MR imaging and its special applications. Radiographics 2009; 29(5): 1433-1449.
27. Howe FA, Robinson SP, McIntyre DJ, Stubbs M, Griffiths JR. Issues in flow and oxygenation dependent contrast (FLOOD) imaging of tumours. NMR Biomed 2001; 14(7-8): 497-506.
28. Hittmair K, Gomiscek G, Langenberger K, Recht M, Imhof H, Kramer J. Method for the quantitative assessment of contrast agent uptake in dynamic contrast-enhanced MRI. Magn Reson Med 1994; 31(5): 567-571.
29. Hendriksen EM, Span PN, Schuuring J, Peters JP, Sweep FC, van der Kogel AJ, Bussink J. Angiogenesis, hypoxia and VEGF expression during tumour growth in a human xenograft tumour model. Microvasc Res 2009; 77(2): 96-103.
30. Findlay M, Young H, Cunningham D, Iveson A, Cronin B, Hickish T, Pratt B, Husband J, Flower M, Ott R. Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: correlation with tumor response to fluorouracil. J Clin Oncol 1996; 14(3): 700-708.
31. Van der Veldt AA, Lubberink M, Bahce I, Walraven M, de Boer MP, Greuter HN, Hendrikse NH, Eriksson J, Windhorst AD, Postmus PE, Verheul HM, Serne EH, Lammertsma AA, Smit EF. Rapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: implications for scheduling of anti-angiogenic drugs. Cancer Cell 2012; 21(1): 82-91.
32. Pastuskovas CV, Mundo EE, Williams SP, Nayak TK, Ho J, Ulufatu S, Clark S, Ross S, Cheng E, Parsons-Reponte K, Cain G, Van Hoy M, Majidy N, Bheddah S, dela Cruz Chuh J, Kozak KR, Lewin-Koh N, Nauka P, Bumbaca D, Sliwkowski M, Tibbitts J, Theil FP, Fielder PJ, Khawli LA, Boswell CA. Effects of anti-VEGF on pharmacokinetics, biodistribution, and tumor penetration of trastuzumab in a preclinical breast cancer model. Mol Cancer Ther 2012; 11(3): 752-762.
33. Heskamp S, Boerman OC, Molkenboer-Kuenen JD, Oyen WJ, van der Graaf WT, van Laarhoven HW. Bevacizumab reduces tumor targeting of antiepidermal growth factor and anti-insulin-like growth factor 1 receptor antibodies. Int J Cancer 2013; 133(2): 307-14.
34. Tol J, Koopman M, Cats A, Rodenburg CJ, Creemers GJ, Schrama JG, Erdkamp FL, Vos AH, van Groeningen CJ, Sinnige HA, Richel DJ, Voest EE, Dijkstra JR, Vink-Borger ME, Antonini NF, Mol L, van Krieken JH, Dalesio O, Punt CJ. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. New Engl J Med 2009; 360(6): 563-572.
35. Lee ST, Scott AM. Hypoxia positron emission tomography imaging with 18F-fluoromisonidazole. Sem Nucl Med 2007; 37(6): 451-461.
36. Oehler C, O'Donoghue JA, Russell J, Zanzonico P, Lorenzen S, Ling CC, Carlin S. 18F-fluromisonidazole PET imaging as a biomarker for the response to 5, 6-dimethylxanthenone-4-acetic acid in colorectal xenograft tumors. J Nucl Med 2011; 52(3): 437-444.
37. Masunaga S, Liu Y, Tanaka H, Sakurai Y, Suzuki M, Kondo N, Maruhashi A, Ono K. Reducing intratumour acute hypoxia through bevacizumab treatment, referring to the response of quiescent tumour cells and metastatic potential. Br J Radiol 2011; 84(1008): 1131-1138.
38. McGee MC, Hamner JB, Williams RF, Rosati SF, Sims TL, Ng CY, Gaber MW, Calabrese C, Wu J, Nathwani AC, Duntsch C, Merchant TE, Davidoff AM. Improved intratumoral oxygenation through vascular normalization increases glioma sensitivity to ionizing radiation. Int J Radiat Oncol Biol Phys 2010; 76(5): 1537-1545.
39. Weisshardt P, Trarbach T, Durig J, Paul A, Reis H, Tilki D, Miroschnik I, Ergun S, Klein D. Tumor vessel stabilization and remodeling by anti-angiogenic therapy with bevacizumab. Histochem Cell Biol 2012; 137(3): 391-401.
40. Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Vinals F, Inoue M, Bergers G, Hanahan D, Casanovas O. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009; 15(3): 220-231.
41. Rapisarda A, Hollingshead M, Uranchimeg B, Bonomi CA, Borgel SD, Carter JP, Gehrs B, Raffeld M, Kinders RJ, Parchment R, Anver MR, Shoemaker RH, Melillo G. Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition. Mol Cancer Ther 2009; 8(7): 1867-1877.
42. Ren Y, Fleischmann D, Foygel K, Molvin L, Lutz AM, Koong AC, Jeffrey RB, Tian L, Willmann JK. Antiangiogenic and radiation therapy: early effects on in vivo computed tomography perfusion parameters in human colon cancer xenografts in mice. Invest Radiol 2012; 47(1): 25-32.
43. Airley RE, Loncaster J, Raleigh JA, Harris AL, Davidson SE, Hunter RD, West CM, Stratford IJ. GLUT-1 and CAIX as intrinsic markers of hypoxia in carcinoma of the cervix: relationship to pimonidazole binding. Int J Cancer 2003; 104(1): 85-91.
44. Mehta S, Hughes N, Jubb A, Turley H, Han C, Li S, Taylor N, Padhani A, Adams R, Makris A, Harris A. Early changes in angiogenesis and hypoxia following bevacizumab therapy in primary breast cancer. J Clin Oncol 2012; 30(suppl; abstr 1066).
45. McIntyre A, Patiar S, Wigfield S, Li JL, Ledaki I, Turley H, Leek R, Snell C, Gatter K, Sly WS, Vaughan-Jones RD, Swietach P, Harris AL. Carbonic anhydrase IX promotes tumor growth and necrosis in vivo and inhibition enhances anti-VEGF therapy. Clin Cancer Res 2012; 18(11): 3100-3111.